Polymer‐free versus permanent polymer drug eluting stents in coronary artery disease: A meta‐analysis of 10 RCTs with 6575 patients

Chronic Diseases and Translational Medicine - Tập 1 - Trang 221-230 - 2015
De-Wei Wu1, Meng-Yue Yu1, Hai-Yang Gao1, Li Zhang1, Fei Song1, Xin-Yue Zhang1, Yong-Jian Wu1
1Coronary Heart Disease Center, National Center for Cardiovascular Diseases and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China

Tóm tắt

AbstractBackgroundPermanent polymer drug eluting stents (PP‐DES) may induce inflammation of the vessel wall due to the existence of the polymer, which may delay intimal healing. Polymer‐free DES (PF‐DES) that eliminate the polymeric carrier may potentially lead to safer DES. However, the safety and efficacy of PF‐DES remains controversial.MethodsRandomized controlled trials comparing PF‐DES with PP‐DES were searched in online database including MEDLINE, Excerpta Medica Database (EMBASE) and Cochrane Library. Studies reporting late lumen loss (LLL), all‐cause death, myocardial infarction (MI), target lesion revascularization (TLR) and late stent thrombosis (LST) were enrolled and quantitatively analyzed.ResultsTen studies enrolling 6575 patients were included in this meta‐analysis. The PF‐DES showed a benefit in reducing all‐cause death (OR = 0.77, 95% CI: 0.61 to 0.98, P = 0.03) and long‐term LLL (weighted mean difference (WMD) −0.16 mm, 95% CI: −0.22 to −0.11 mm, P < 0.001), while no superiority was found in reducing short‐term LLL (WMD 0.03 mm, 95% CI: −0.07–0.13 mm, P = 0.57), MI (OR = 1.12, 95% CI: 0.19 to 23.18, P = 0.39), TLR (OR = 1.19, 95% CI: 0.42 to 3.38, P = 0.83) and LST (OR = 0.92, 95% CI: 0.05 to 5.71, P = 0.74).ConclusionPF‐DES showed benefits in reducing long‐term LLL and mortality compared with PP‐DES, but no superiority was found in short‐term LLL, MI, TLR and LST. These findings provide a sound basis for the wide application of PF‐DES in the future.

Tài liệu tham khảo

10.1056/NEJMoa035071 10.1056/NEJMoa032441 10.1161/CIRCULATIONAHA.106.180944 10.1161/CIRCULATIONAHA.106.675934 10.1161/CIRCULATIONAHA.107.693739 10.1016/j.jacc.2006.03.042 Julian P.T., 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011) 10.1161/CIRCULATIONAHA.106.685313 10.1016/j.jacc.2012.08.055 10.1016/j.jacc.2010.03.020 10.1136/hrt.2009.172379 10.1016/j.jacc.2011.12.009 10.1002/ccd.24375 10.1161/CIRCULATIONAHA.111.026732 10.1002/ccd.25131 Dang Q., 2012, Six‐month angiographic and one‐year clinical outcomes of polymer free paclitaxel‐eluting stent in patients with ST‐segment elevation myocardial infarction: a comparison with permanent polymer sirolimus‐eluting stent, Chin Med J, 125, 3393 Zhang Y., 2014, Nine‐month angiographic and two‐year clinical follow‐up of polymer‐free sirolimus‐eluting stent versus durable‐polymer sirolimus‐eluting stent for coronary artery disease: the nano randomized trial, Chin Med J, 127, 2153 10.1161/CIRCINTERVENTIONS.113.000800 10.1016/j.ijcard.2013.03.034 10.1016/j.cardiores.2004.04.029 10.1161/CIRCULATIONAHA.107.730010 10.1161/01.CIR.0000116202.41966.D4 10.1161/CIRCULATIONAHA.104.508937 10.1161/CIRCULATIONAHA.109.854398 10.1016/j.jacc.2011.01.011 10.1177/2047487312467745 10.1161/01.CIR.94.7.1690 10.1111/j.1540-8183.2012.00722.x 10.1016/j.jacc.2011.10.256 10.1016/j.jcin.2008.11.015 10.1161/01.CIR.0000164271.01172.1A 10.1016/j.biomaterials.2004.06.026
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 1

221-230

Thông tin tác giả